In adult, Lenvatinib 10mg is indicated for the treatment of metastatic, progressive, radioactive Differentiated Thyroid cancer.
Lenvatinib 10mg in combination with everolimus is indicated in patients for the treatment of advance Renal Cell Carcinoma following treatment before anti-angiogenic therapy.
Lenvatinib 10mg is also indicated for the first line treatment in patients suffering with unresectable hepatocellular carcinoma.
Lenvatinib is a tyrosine kinase inhibitor which has shown mainly anti-angiogenic properties, and direct prevention of malignant developed was also observedinside the models.
Lenvatinib which selectively prevents the kinase functions of vascular endothelial growth factor receptors 1(FLT1), 2 (KDR), 3 (FLT4), Although not been studied directly with Lenvatinib, the mechanism of action (MOA) for High blood pressure is hypothesizing to be resolve by the prevention of VEGFR2 in vascular endothelial cells. Same as the, the action for proteinuria is hypothesizing to be interfere with down regulation of VEGFR1 and VEGFR2 in the cell of bowman’s capsules of the glomerulus.
Ingredients : Lenvatinib
Strength : 10mg
Manufactured : Eisai Co. Ltd
Package : 20 Capsules
The usual dose of Lenvatinib for the adult patients is 24mg and administer has two 10mg capsules and one 4mg capsule given orally, once daily taken with or without food. The Lenvatinib tablet should continue until disease progression or until unacceptable toxicity occurs. Take Lenvatinib tablet at the same time. Patients with severe renal or hepatic impairment the dose is 14mg administer once daily orally.OVERDOSE
Lenvatinib is not expected to be dialyzable because of maximum plasma protein binding and if the dose getting of Lenvatinib 120mg orally then causes death due to multiorgan dysfunction occurred in the patients.
Tiredness Peeling of skin on palms and sole of the feet Constipation Loss of appetite Weight loss Joint and muscle pain InsomniaSerious side effects
Shortness of breath Chest pain Pain in arm, back, neck or jaw Seizures Black, tarry or bloody stools Heavy menstrual bleeding Coughing up blood Yellowing of the skin or eyes
Lenvatinib 10mg combination with Carboplatin, paclitaxel has no specific pharmacokinetics impact Interaction with CYP3A, Pglycoprotein (P-gp) inhibitors and inducers has no dose adjustment for Lenvatinib 10mg.